Thursday, 20 Sep 2018

You are here

EULAR 2018 - Day 3 Report

Behcet’s Responds to Apremilast – We missed reporting this one on Wednesday when Hatemi et al presented the results of a phase 3 trial of apremilast (APR) vs placebo (PBO) in active Behcet’s with oral ulcers, with ≥3 OU at the start. BD patients (n-207) were randomized (1:1) to APR 30 mg BID or PBO (n=103) for 12 weeks, followed by a 52-week active-treatment extension.  The total number of Oral Ulcers was statistically significantly lower in the APR group compared with the PBO group. Numerically greater number of patients had resolution of genital ulcers at Week 12 in the APR group.  It appears this drug is headed to the FDA for decision later this year.

Biologics Do Not Differentially Affect TKR/THR Post-Operative Infection Rates  – a review of the claims data looked at over 11,000 RA patients on biologics (Abatacept, Adalimumab, Etanercept, Infliximab and fewer on Rituximab or Tocilizumab). (OP0228). The post-op hospitalized infection rate was 6.6 to 8.5% and was not significant between biologics (similar for the 30 day readmission rate). This was clearly different with steroid use which showed a dose related increased risk of hospitalized infection and 30 day readmission for infection, with a 2 fold increase risk for those receiving prednisone > 10 mg per day.  Similarly prosthetic joint infections were increased with increasing steroid use but were similar in frequency with biologics. Tocilizumab was associated with a higher risk of prosthetic infections, but this finding is less certain given the lower, limited number of TCZ treated patients in this cohort. (Correction: this article has been updated to reflect the correct abstract, OP0228. We apologize for any inconvenience.)

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Managing Comorbidity and Poor Drug Responses

Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.